Stevens Capital Management’s TherapeuticsMD TXMD Stock Holding History

Stevens Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-307	Closed	-$101K	–	934
2018 Q3	$101K	Buy	+307	New	+$94.1K	﹤0.01%	676
2017 Q1	–	Sell	-207	Closed	-$60K	–	1111
2016 Q4	$60K	Sell	207 -17	-8%	-$5.27K	﹤0.01%	830
2016 Q3	$76K	Buy	+224	New	+$81.8K	﹤0.01%	863
2015 Q2	–	Sell	-302	Closed	-$91K	–	1253
2015 Q1	$91K	Buy	302 +11	+4%	+$2.69K	﹤0.01%	927
2014 Q4	$65K	Sell	291 -578	-67%	-$119K	﹤0.01%	951
2014 Q3	$202K	Buy	869 +595	+217%	+$150K	0.01%	858
2014 Q2	$61K	Sell	274 -85	-24%	-$18.9K	﹤0.01%	1016
2014 Q1	$113K	Buy	+359	New	+$114K	﹤0.01%	1003

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Stevens Capital Management's TXMD Position: Q4 2018 in Review

Stevens Capital Management sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 307 shares — an estimated $101K sold.

Stevens Capital Management first reported a position in TXMD in Q1 2014 and held it in 8 quarters. The position peaked at $202K in Q3 2014. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

Stevens Capital Management reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
Stevens Capital Management sold 307 TherapeuticsMD shares in Q4 2018, an estimated $101K.
Stevens Capital Management first reported a position in TherapeuticsMD in Q1 2014 and held it in 8 quarters.
Stevens Capital Management's TherapeuticsMD position peaked at $202K in Q3 2014.
140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Stevens Capital Management's 13F filing for Q4 2018, filed 6 Feb 2019.